Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 70,200 shares, a drop of 16.9% from the February 28th total of 84,500 shares. Currently, 2.6% of the company’s shares are short sold. Based on an average daily volume of 415,800 shares, the days-to-cover ratio is currently 0.2 days.
Hedge Funds Weigh In On Theriva Biologics
A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP purchased a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is currently owned by institutional investors.
Theriva Biologics Trading Up 1.8 %
Theriva Biologics stock traded up $0.02 during trading hours on Tuesday, hitting $1.12. 15,735 shares of the stock traded hands, compared to its average volume of 994,860. Theriva Biologics has a one year low of $1.02 and a one year high of $12.28. The business’s 50-day moving average price is $1.38. The stock has a market capitalization of $3.11 million, a P/E ratio of -0.03 and a beta of 1.22.
About Theriva Biologics
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
See Also
- Five stocks we like better than Theriva Biologics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- ETF Screener: Uses and Step-by-Step Guide
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
